Rodela

Trials Intel automates clinical trial intelligence for pharma investors using Gemini's multimodal capabilities. The agent autonomously monitors ClinicalTrials.gov, classifies trials by therapeutic area and commercial potential, then uses Gemini Vision to extract quantitative data from survival curves and adverse event tables in published trial results. It synthesizes insights across multiple sources to generate market trends, investment opportunities, and competitive intelligence. What currently requires teams of analysts at $100-500K/year is automated in minutes. Built entirely with Google Gemini 2.0 for true text + vision multimodal analysis.